From Donor to Oncology Diagnostic: Where Your Sample Goes, and Why It Matters

By Inga Rose, CEO, Reference Medicine

There is a moment in cancer care that passes quickly, unremarkably, but carries lasting significance. 

When a patient shows symptoms of cancer or is diagnosed with cancer, the medical oncology team will map out a clinical plan, which may include surgical removal of suspicious tissue. As a treatment plan is taking shape, patients are asked whether they are willing to donate a portion of their sample for research.

It is a simple question, often asked alongside many others, and most patients answer it just as simply. They say yes. 

That decision sets in motion a ripple effect with lasting impact.

It begins in the middle of care

During surgery or biopsy, the sample of suspicious tissue is collected to help confirm what kind of cancer the patient has, how advanced it is, and what characteristics might influence the next step. The clinical team is focused on the person in front of them and the decisions that need to be made quickly and carefully.

After the sample has served its purpose for the patient, and once pathology teams have confirmed the diagnosis and treatment planning is underway, there is often material that is no longer required for clinical care. This is the donated sample that drives research.

First, the sample is carefully de-identified to protect patient privacy. Names, dates of birth, and any direct identifiers are removed and replaced with a research ID number, allowing the sample to be used beyond the hospital while protecting the individual patient.

The sample transitions from being part of one patient’s care journey to becoming part of a broader research system designed to understand disease in a way that can benefit others.

The work behind the scenes is deliberate

For samples donated to Reference Medicine’s program, sample processing starts immediately at the hospital - every minute counts. Blood is separated into its components, tissue is preserved or frozen, and each step is tracked. Handling pre-analytical details like timing, temperature, and preparation directly influences whether a sample will remain usable and whether the data generated from it can be trusted.

Donation pathways can vary across research programs, but for Reference Medicine, the next steps are just as critical to downstream research as the tightly controlled processing and data collection performed at the hospital. Once a sample arrives in Reference Medicine’s lab, it goes through another layer of verification. Teams log each specimen, confirm that it arrived in the expected condition, and check for any signs of degradation. Pathologists review the material again, sometimes confirming the original diagnosis and occasionally identifying discrepancies that require follow-up. Molecular teams extract DNA to evaluate both quantity and quality, ensuring that the sample meets defined thresholds for research use.

A sample becomes a resource

By the time a biospecimen is ready for research, it has taken on a new level of value. It is no longer just tissue or blood. It is paired with carefully curated, de-identified clinical data that provides essential context, including information about the disease, its stage, genetic biomarkers and relevant patient characteristics like gender, age or ethnicity.

These details allow researchers to ask better questions and interpret results in a way that reflects real patient experiences.

Researchers' access to these samples through biobanks is tightly controlled. Samples are shared under custodial agreements that reflect explicit patient consent, and they are placed with researchers working toward clearly defined goals. This might include developing new diagnostic tests, refining existing tools, or deepening understanding of how certain cancers behave.

Where innovation begins to take shape

Once in the hands of researchers, these donated biospecimens become foundational to clinical research and diagnostic development. They provide the complexity and variability that cannot be replicated in any other way, allowing researchers to evaluate whether a test is accurate, reliable, and clinically meaningful. They also allow for measurement of sensitivity and specificity, which are critical for determining whether a diagnostic is viable and reproducible in real-world settings.

Over time, some of these efforts progress through validation and regulatory review, and eventually into clinical practice. When that happens, the impact becomes real, with improved detection, more informed treatment decisions, and better tools for monitoring disease.

All from a simple sample donation.

A contribution that continues forward

Most patients will never follow their sample beyond the moment they agree to donate it. They might not even remember that they agreed to the donation. Still, their role is essential to innovation and progress in oncology care.

What begins as a small decision within a clinical setting becomes part of something much larger - connecting individual experiences to future advances for the benefit of patients everywhere.

‍